Current highlights

  1. Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder

    Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder

    Abstract Full Text Full Text PDF (0,9 MB) Patient Summary
  2. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses

    Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses

    Abstract Full Text Full Text PDF (1,4 MB) Patient Summary
  3. Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial

    Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial

    Abstract Full Text Full Text PDF (515 KB) Patient Summary
  4. European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review

    European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review

    Abstract Full Text Full Text PDF (858 KB)
  5. Diagnosing the Pathophysiologic Mechanisms of Nocturnal Polyuria

    Diagnosing the Pathophysiologic Mechanisms of Nocturnal Polyuria

    Abstract Full Text Full Text PDF (764 KB) Patient Summary

Hot off the press

  1. Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma

    Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma

    Abstract Full Text Full Text PDF (282 KB) Patient Summary
    Corrected
  2. Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma

    Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma

    Abstract Full Text Full Text PDF (570 KB)
    Corrected
  3. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

    ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

    Abstract Full Text Full Text PDF (1,0 MB) Patient Summary
    Corrected